Trademark: 88751602
Status Date
Friday, June 10, 2022
Filing Date
Wednesday, January 8, 2020
Published for Opposition
Tuesday, July 28, 2020
Abandoned Date
Thursday, June 9, 2022
5 therapeutic preparations, namely, antibodies for use in targeting the CCR5 cell receptor; therapeutic preparations for the treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; therapeutic preparations for the prevention of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19
44 providing a website featuring medical information; providing a website featuring information in the field of antibodies for use in targeting the CCR5 cell receptor; providing health and medical information, namely, providing a website featuring information in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; all of the forgoing excluding information directed to adjuvants for vaccines and molecular genetics and genomics testing and reporting
42 scientific research consulting services in the field of immunology; scientific research consulting services in the field of antibodies for use in targeting the CCR5 cell receptor; scientific research consulting services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services; medical research services in the field of antibodies for use in targeting the CCR5 cell receptor; medical research services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; all of the foregoing excluding medical research and scientific research consulting services directed to adjuvants for vaccines and molecular genetics and genomics testing and reporting
Jun 10, 2022
Abandonment Notice E-Mailed - After Publication
Jun 10, 2022
Abandonment - After Publication
Jun 9, 2022
Teas Express Abandonment Received
Mar 24, 2022
Notice Of Approval Of Extension Request E-Mailed
Mar 22, 2022
Sou Extension 3 Granted
Mar 22, 2022
Sou Extension 3 Filed
Mar 22, 2022
Teas Extension Received
Aug 14, 2021
Notice Of Approval Of Extension Request E-Mailed
Aug 12, 2021
Sou Extension 2 Granted
Aug 12, 2021
Sou Extension 2 Filed
Aug 12, 2021
Teas Extension Received
Mar 19, 2021
Notice Of Approval Of Extension Request E-Mailed
Mar 17, 2021
Sou Extension 1 Granted
Mar 17, 2021
Sou Extension 1 Filed
Mar 17, 2021
Teas Extension Received
Sep 22, 2020
Noa E-Mailed - Sou Required From Applicant
Jul 28, 2020
Official Gazette Publication Confirmation E-Mailed
Jul 28, 2020
Published For Opposition
Jul 8, 2020
Notification Of Notice Of Publication E-Mailed
Jun 24, 2020
Approved For Pub - Principal Register
Jun 24, 2020
Examiner's Amendment Entered
Jun 24, 2020
Notification Of Examiners Amendment E-Mailed
Jun 24, 2020
Examiners Amendment E-Mailed
Jun 24, 2020
Examiners Amendment -Written
Jun 23, 2020
Teas/Email Correspondence Entered
Jun 22, 2020
Correspondence Received In Law Office
Jun 22, 2020
Teas Response To Office Action Received
Mar 27, 2020
Notification Of Non-Final Action E-Mailed
Mar 27, 2020
Non-Final Action E-Mailed
Mar 27, 2020
Non-Final Action Written
Mar 26, 2020
Assigned To Examiner
Jan 13, 2020
New Application Office Supplied Data Entered In Tram
Jan 11, 2020
New Application Entered In Tram
Trademark Alertz updated from USPTO on 2030-01-24
